证券日报网讯2月9日，中国宝安（000009）在互动平台回答投资者提问时表示，国际精密线性伺服执行 器目前处于研发迭代阶段，产品还未成熟。 ...

（文章来源：证券日报） 证券日报网讯 2月9日，中国宝安在互动平台回答投资者提问时表示，截至2026年1月20日，公司股东总 户数约为14.80万户。 ...

Core Viewpoint - China Baoan has stated that it conducts investor question responses in accordance with regulations [2] Group 1 - The company engages with investors through a platform to address their inquiries [2]

Group 1 - XianDao Intelligent has set the final price for its H-share public offering at HKD 45.8 per share, with expected listing on February 11, 2026 [1] - Jida Communication is a candidate for a project with China Mobile, with an estimated service fee of approximately CNY 51.04 million [2] - Bowei Alloy's controlling shareholder plans to increase holdings by CNY 100 million to 150 million from February 10 to August 9, 2026 [3] Group 2 - Xiamen Airport reported 16,368 aircraft takeoffs and landings in January 2026, a year-on-year decrease of 4.82%, with passenger throughput of 2.38 million, down 3.84% [4] - Yitong Century has won a bid for a project worth CNY 107 million, providing comprehensive maintenance services for China Tower [5] - Huayi Brothers' controlling shareholder's 70 million shares are subject to judicial auction, representing 42.89% of his holdings and 2.52% of the company's total shares [6] Group 3 - Lianhuan Pharmaceutical received approval for the sale of Tadalafil tablets (20mg) in Ghana [7] - Aonong Biological reported a pig sales volume of 166,600 in January 2026, a year-on-year increase of 35.36% [8] - Xiantan Co. achieved chicken product sales revenue of CNY 546 million in January 2026, a year-on-year increase of 54.9% [9] Group 4 - Zhengbang Technology reported a January sales revenue of CNY 816 million from pig sales, a year-on-year increase of 19.69% [10] - Qianjin Pharmaceutical's net profit for 2025 grew by 24.74% to CNY 288 million [11] - Xinhua Pharmaceutical received a drug registration certificate for glucosamine sulfate capsules [12] Group 5 - Yuandong Bio completed the first dosing of its EP-0210 monoclonal antibody in a Phase I clinical trial for inflammatory bowel disease [13] - Jiaokong Technology signed a contract for the Sydney Metro West Line signal system subcontracting project worth AUD 93.53 million [14] - Dangsheng Technology signed a strategic cooperation framework agreement with Huineng Technology in solid-state batteries and the new energy industry [15] Group 6 - Jinhui Co. plans to acquire 100% of Fusheng Mining for CNY 210 million [16] - Cangzhou Mingzhu announced Guangzhou Light Industry as its new controlling shareholder after a share transfer [17] - Dingxin Technology's vice president was fined CNY 120,000 for short-term trading [18][19] Group 7 - China Modern Pharmaceutical's subsidiary passed a GMP compliance inspection for its production line [20] - Chaosheng Electronics plans to increase capital by CNY 400 million in its subsidiary to enhance competitiveness [21] - Lonyu Mountain reported a 25.03% year-on-year increase in pig sales revenue in January 2026 [22] Group 8 - Sanbo Brain Science's chairman has been released from investigation, and the company is operating normally [23] - Hainan Mining is planning to acquire control of Luoyang Fengrui Fluorine Industry and will resume trading on February 10, 2026 [24] - Dongwei Technology's net profit for 2025 increased by 86.81% [25] Group 9 - Yuanjie Technology plans to invest CNY 1.251 billion in a semiconductor chip and device R&D production base [26] - Metro Design signed a contract for an energy management project with Guangzhou Metro Group worth CNY 924 million [27] - Zhongmin Energy intends to acquire 51% of Fujian Yongtai Mintou Pumped Storage Co. for CNY 864 million [28] Group 10 - Dianzhi Technology plans to repurchase shares worth CNY 100 million to 200 million [29] - China Baoan was not selected as a restructuring investor for the Singshan Group [30] - Zhiguang Electric's subsidiary signed a CNY 1.004 billion contract for energy storage systems [31] Group 11 - Zhifei Biological received approval for a clinical trial of its herpes zoster vaccine [32] - KQ Bio received a new veterinary drug registration certificate for a vaccine against porcine circovirus type 2 [33] - Huanxu Electronics reported a 4% year-on-year increase in consolidated revenue for January 2026 [34] Group 12 - Xiangjia Co. reported a 10.42% year-on-year increase in live poultry sales revenue in January 2026 [35] - Kemin Foods' subsidiary reported a 68.29% year-on-year increase in pig sales revenue in January 2026 [36] - Liyuan Technology signed a procurement contract worth CNY 54.98 million [37] Group 13 - Jiuqiang Bio received a medical device registration certificate for a fibrin degradation product detection kit [38] - Zhongguancun's subsidiary passed the consistency evaluation for Tramadol Hydrochloride tablets [39] - Rundou Co. received a drug registration certificate for Candesartan Etil [40]

格隆汇2月9日丨中国宝安(000009.SZ)公布，根据宁波杉杉股份（维权）有限公司于2026年2月9日披露 的《宁波杉杉股份有限公司关于控股股东及其子公司签署重整投资协议的公告》（公告编号：2026- 004），公司及所牵头的联合体未中选成为杉杉集团及其全资子公司宁波朋泽实质合并重整的重整投资 人。根据杉杉集团和宁波朋泽合并重整案管理人之文件规定，杉杉集团和宁波朋泽合并重整案管理人将 退返公司前期缴纳的尽调保证金。 ...

Group 1 - China Baoan (000009.SZ) announced that it and the consortium it led were not selected as the restructuring investors for the substantive merger and restructuring of Shanshan Group and its wholly-owned subsidiary Ningbo Pengze [1] - The announcement is based on the disclosure by Ningbo Shanshan Co., Ltd. regarding the signing of a restructuring investment agreement by its controlling shareholder and its subsidiaries [1] - As per the documents from the administrators of the merger and restructuring case, the administrators will return the due diligence deposit previously paid by the company [1]

关于参与杉杉集团及其全资子公司实质合并 重整投资人招募的进展公告 证券代码：000009 证券简称：中国宝安 公告编号：2026-001 中国宝安集团股份有限公司 敬请投资者理性投资，注意投资风险。 特此公告 中国宝安集团股份有限公司董事局 二〇二六年二月十日 1 本公司及董事局全体成员保证信息披露内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏。 中国宝安集团股份有限公司（以下简称"公司"）于 2025 年 12 月 13 日披 露了《关于参与杉杉集团及其全资子公司实质合并重整投资人招募的公告》（公 告编号：2025-044），公司作为重整投资联合体（以下简称"联合体"）牵头人， 联合下属子公司贝特瑞新材料集团股份有限公司及其他潜在投资人参与杉杉集 团有限公司（以下简称"杉杉集团"）及其全资子公司宁波朋泽贸易有限公司（以 下简称"宁波朋泽"）的实质合并重整投资人招募。 根据宁波杉杉股份有限公司于 2026 年 2 月 9 日披露的《宁波杉杉股份有限 公司关于控股股东及其子公司签署重整投资协议的公告》（公告编号：2026-004）， 公司及所牵头的联合体未中选成为杉杉集团及其全资子公司宁波朋泽实 ...

中国宝安公告称，公司于2025年12月13日披露参与杉杉集团及其全资子公司实质合并重整投资人招募， 作为联合体牵头人，联合下属子公司贝特瑞及其他潜在投资人参与。根据宁波杉杉2月9日公告，公司及 所牵头的联合体未中选成为重整投资人。按规定，杉杉集团和宁波朋泽合并重整案管理人将退返公司前 期缴纳的尽调保证金。 ...

1、资料名称：2024-2001年上市公司企业突破式绿色创新数据 2、测算方式：参考c刊《经济管理》李哲老师的做法，突破式创新改变了公司过往创新路径， 拓展了既有技术能力边界， 对技术变革产生深远影响， 有助 于公司积累长期竞争力。有鉴于此， 本文构建以下四种公司突破性创新的测度方式计算公司对新技术的探索程度， 由公司进入的专利二级分类数量代表， 表示为 InnStr_Class。我国专利分类采用 《 国际专利分类表》 的IPC 分类。IPC 分类按照技术主题设立类目， 共有 131 个二级专利分类数， 使用者可通过 专利分类考察申请专利的突破性和创造性。当公司进入了过往没有进入的专利分类， 则表明公司在不熟悉的技术领域进行了实验和探索， 创造了新知识。 这是因为， 如果公司过去未在该专利分类下申请专利， 则代表该技术领域对公司而言是不熟悉的。技术知识随着时间折旧和变废， 如果公司未持续投入该 技术， 将导致该技术的知识存量显著下降， 与新技术的相关性也显著更低。Ahuja 和 Lampert( 2001) ［ 31 ］方法基于美国 400 个专利技术分类， 将技术知 识折旧年限设为五年。本文根据 IPC 分 ...

1.资料名称：2024-2000年上市公司企业传统企业跨界绿色数字创新数据 2.测算方式：参考顶刊《中国工业经济》陶锋（2025）老师的做法，具体如下图文献所示。首先，根据前文的定义，参考国家统计局发布的《数字经济及其 核心产业统计分类（2021）》（简称《分类》），本文将行业分类属于数字经济核心产业的企业界定为数字企业，其他则为传统企业。考虑到研究样本为上 市公司，结合《中国上市公司协会上市公司行业统计分类指引》，将属于计算机、通信和其他电子设备制造业，电信、广播电视和卫星传输服务业，互联网 和相关服务业以及软件和信息技术服务业的上市公司认定为数字企业，其他则为传统企业，这与《分类》的界定基本一致。然后，根据数字技术领域的IPC 信息，本文识别了上市公司数字技术发明专利，进而考察传统企业跨界数字创新。关于数字技术发明专利的识别步骤和指标测量的具体说明如下：①从 IncoPat数据库获取中国发明专利数据，并根据专利申请人名称，识别和匹配了上市公司的发明专利。②基于《数字经济核心产业分类与国际专利分类参照 关系表（2023）》提供的数字技术领域专利IPC信息，据此与每个发明专利的IPC分类号进行识别和匹配。如果 ...